Immunoglobulin Or Antibody Binds A Microorganism Or Normal Or Mutant Component Or Product Thereof (e.g., Animal Cell, Cell Surface Antigen, Secretory Product, Etc.) Patents (Class 435/332)
  • Patent number: 5837539
    Abstract: The invention relates to isolated human mesenchymal stem cells, a method for isolating, purifying, and culturally expanding human mesenchymal stem cells (i.e. mesenchymal stem cells or "MSCs"), and characterization of (including by cytokine expression profiling) and uses, particularly research reagent, diagnostic and therapeutic uses for such cells. The stem cells can be culture expanded without differentiating. Further disclosed are monoclonal antibodies specific for human mesenchymal stem cells and the monoclonal hybridoma cell lines (ATCC nos. 10743-10745) that synthesize and secrete these monospecific antibodies, and uses of the monoclonal antibodies for diagnostic and/or therapeutic purposes.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: November 17, 1998
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Arnold I. Caplan, Stephen E. Haynesworth
  • Patent number: 5834187
    Abstract: The invention relates to the isolation and cloning of the structural gene, hipP, for the NTHi pili serotype 5 and the LKP operon. The invention relates to DNA molecules capable of hybridizing to the DNA sequences of the Haemophilus influenzae genome related to the pili. The invention further relates to a DNA molecule which encodes a pili protein, particularly a tip adhesion protein. The DNA molecules of the invention can be used in a method for assaying a sample, such as a blood sample, for the presence of Haemophilus influenzae in the sample. Accordingly, the invention further relates to the use of the DNA molecules as a diagnostic. The invention also relates to a recombinant Haemophilus influenzae pili protein, such as a tip adhesion protein. The protein can be employed in a method for immunizing an animal, such as a human, as a therapeutic or diagnostic.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 10, 1998
    Assignee: Bactex, Inc.
    Inventors: Bruce A. Green, Charles C. Brinton, Jr.
  • Patent number: 5830469
    Abstract: The present invention provides a panel of monoclonal antibodies and binding proteins which specifically bind to human Fas antigen. Some of the antibodies and binding proteins are capable of stimulating T cell proliferation, inhibiting binding of anti-Fas CH-11 monoclonal antibody to cells expressing Fas antigen, blocking anti-Fas CH-11 monoclonal antibody-mediated lysis of cells, and blocking Fas ligand-mediated lysis of cells. The invention also provides for therapeutic compositions comprising the monoclonal antibodies.
    Type: Grant
    Filed: April 26, 1995
    Date of Patent: November 3, 1998
    Assignee: Immunex Corporation
    Inventors: David H. Lynch, Mark R. Alderson
  • Patent number: 5830667
    Abstract: Human P450 IID6 cytochrome-derived peptide fragments, anti peptide anti fragment antibodies and applications thereof in the diagnosis of autoimmune hepatitis and more especially in the differential diagnosis between autoimmune hepatitis and other chronic viral forms of hepatitis, such as hepatitis C or B. Said human P450 cytochrome peptide fragment contains at least one P450 IID6 cytochrome immunodominant epitope and consists of an amino acid sequence comprising from 3 to 70 amino acids. Said peptide binds specifically with anti-LKM auto-anitbodies produced in autoimmune hepatitis.
    Type: Grant
    Filed: April 18, 1994
    Date of Patent: November 3, 1998
    Assignee: Institut National de la Sante et de la Recherche Medicale-INSERM
    Inventor: Fernando Alvarez
  • Patent number: 5820858
    Abstract: This invention provides monoclonal antibodies that bind to the cell surface CD14 receptor and soluble CD14 receptor. The antibodies are useful for the detection of the presence of cell surface and soluble CD14 in a sample. Chimeric and CDR grafted antibodies generated from the above monoclonal antibodies are further provided. Pharmaceutical compositions containing the above biological compositions are provided. These are useful to treat and prevent LPS-associated disorders, such as sepsis.
    Type: Grant
    Filed: January 23, 1995
    Date of Patent: October 13, 1998
    Assignee: The Scripps Research Institute
    Inventors: Didier J. Leturcq, Ann M. Moriarty, Richard J. Ulevitch, Peter S. Tobias, John C. Mathison
  • Patent number: 5817313
    Abstract: The invention provides a novel treatment of cancer using a monoclonal antibody that recognizes cell surface antigens present on a number of tumor cells, including ovarian, esophageal and cervical carcinomas. A preferred monoclonal antibody is secreted by a hybridoma deposited with the ATCC and has Accession NO. HB 10570.
    Type: Grant
    Filed: April 8, 1996
    Date of Patent: October 6, 1998
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Mark C. Willingham, Kai Chang, Ira Pastan
  • Patent number: 5817515
    Abstract: Monoclonal antibodies, and hybridomas that express the antibodies, which are immunospecific for a novel human .beta..sub.2 integrin alpha subunit polypeptide are disclosed.
    Type: Grant
    Filed: February 22, 1996
    Date of Patent: October 6, 1998
    Assignee: ICOS Corporation
    Inventors: W. Michael Gallatin, Monica Van der Vieren
  • Patent number: 5817311
    Abstract: The present invention relates to a LO-CD2a antibody and methods of using such antibodies or molecules that bind to the same epitope (or a portion thereof) to prevent and inhibit an immune response in human patients, preferably, where the immune response is mediated by the activation and proliferation of T cells or natural killer cells. The administration of an effective amount of the LO-CD2a antibody to a human patient will prevent or inhibit graft rejection, graft versus host disease or autoimmune disease.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 6, 1998
    Assignee: Universite Catholique de Louvain
    Inventors: Herve Bazin, Dominque Latinne
  • Patent number: 5807550
    Abstract: The present invention is directed to antibodies, in particular monoclonal antibodies, which specifically bind to somatotropin binding proteins of animals, but not with the corresponding somatotropin receptors. The antibodies may be used alone to enhance the growth of animals, or may be used together with somatotropin to potentiate the effect of somatotropin in animals. The antibodies may also be used to assay the level of somatotropin binding protein of animals.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: September 15, 1998
    Assignee: American Cyanamid Company
    Inventors: William Robert Baumbach, Bosco Shang Wang, Homayoun Sadeghi, John Steele Logan, Ian C. Hart
  • Patent number: 5801227
    Abstract: The present invention provides monoclonal antibodies and binding proteins which specifically bind to CD40 and are capable of blocking binding of CD40 to CD40 ligand.
    Type: Grant
    Filed: September 8, 1995
    Date of Patent: September 1, 1998
    Inventors: William C. Fanslow, III, JoDee Zappone, Mark Alderson, Richard J. Armitage
  • Patent number: 5798213
    Abstract: The present invention provides monoclonal antibodies against peptides having an amino acid sequence described in Sequence No. 1 or No. 2, the peptides being found in human thymidine phosphorylase and human platelet-derived endothelial cell growth factor. The Invention also provides an immunoassay for human thymidine phosphorylase and/or human platelet-derived endothelial cell growth factor using the monoclonal antibodies. The monoclonal antibodies of the invention recognize human thymidine phosphorylase and human platelet-derived endothelial cell growth factor, and thus are useful in the diagnosis and treatment of various tumors and their metastasis and diseases accompanying abnormal angiogenesis.
    Type: Grant
    Filed: August 21, 1996
    Date of Patent: August 25, 1998
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Kazutaka Miyadera, Yuji Yamada, Yuji Takebayashi, Shinichi Akiyama
  • Patent number: 5786456
    Abstract: A new B-cell receptor, Bp50, a 50 kilodalton polypeptide, that functions in B-cell proliferation is described. Ligands such as lymphokines, antibody molecules or the Fv fragments of antibody molecules that bind to Bp50 and augment the proliferation of activated B-cells can be used to regulate B-cell proliferation or differentiation.
    Type: Grant
    Filed: September 20, 1993
    Date of Patent: July 28, 1998
    Assignee: Oncogen
    Inventors: Jeffrey A. Ledbetter, Edward A. Clark
  • Patent number: 5776775
    Abstract: A hybridoma cell line produced by the fusion of NS-1 myeloma cells with spleen cells obtained from mice immunized with Leukocyte Adhesion Molecule-1 (LAM-1) cDNA transfected cells. The cell line produces a monoclonal antibody reactive with human, monkey, cow, rabbit, sheep, dog, cat, pig and goat LAM-1. The monoclonal antibody produced by the cell line, anti-LAMl-3, may be clinically useful in blocking leukocyte entry into sites of inflammation or tissue injury.
    Type: Grant
    Filed: March 21, 1994
    Date of Patent: July 7, 1998
    Assignee: Dana-Farber Cancer Institute
    Inventors: Thomas F. Tedder, Olivier G. Spertini
  • Patent number: 5773233
    Abstract: The present invention relates to a monoclonal antibody showing a high specificity to Nitrosomonas europaea or Nitrobacter agilis, and a monoclonal antibody-sensitized latex for detecting Nitrosomonas europaea or Nitrobacter agilis used for facilitating the detection of nitrifying bacteria present in activated sludge, water, soil or microorganism-immobilized carriers, and besides a method of detecting nitrifying bacteria using said monoclonal antibody-sensitized latex. The present invention provides a monoclonal antibody to nitrifying bacteria having ammonia oxidation activities or nitrite oxidation activities present in activated sludge or soil, or microorganism-immobilized carriers. This monoclonal antibody to Nitrosomonas europaea or Nitrobacter agilis is prepared by culturing clones of fused cells (hybridomas) obtained by fusing antibody-forming cells and tumor cells obtained from an animal immunized with Nitrosomonas europaea or Nitrobacter agilis.
    Type: Grant
    Filed: October 30, 1996
    Date of Patent: June 30, 1998
    Assignee: Kabushiki Kaisha Yakult Honsha
    Inventors: Hiroshi Ohmura, Takekazu Okumura, Fumiko Nagai
  • Patent number: 5773292
    Abstract: The present invention is directed to the use of antibodies or binding portions thereof or probes which recognize an antigen of normal, benign, hyperplastic, and cancerous prostate epithelial cells or portions thereof. These antibodies or binding portions thereof or probes can be labeled and used for detection of such cells. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate cancer. Also disclosed is a hybridoma cell line which produces a monoclonal antibody recognizing antigens of normal, benign, hyperplastic, and cancerous prostate epithelial cells or portions thereof.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: June 30, 1998
    Assignee: Cornell University
    Inventor: Neil H. Bander
  • Patent number: 5766946
    Abstract: A monoclonal antibody that recognises a structurally continuous and extracellularly-located epitope of human P-glycoprotein is described. The monoclonal antibody has a continuous amino acid sequence, and a binding affinity for the P-glycoprotein which manifests in the ability to stain greater than 90% of live CEM-VBL10 cells in a flow cytometry assay.
    Type: Grant
    Filed: December 15, 1994
    Date of Patent: June 16, 1998
    Assignee: Instituto Superiore Di. Sanita'
    Inventor: Maurizio Cianfriglia
  • Patent number: 5767247
    Abstract: Using human annexin-V or human annexin-V plus dog annexin-V as antigen(s), hybridoma cell lines are prepared which are capable of producing anti-annexin-V monoclonal antibodies having a binding specificity to antigenic determinant site on annexin-V as antigenic protein and belonging to immunoglobulin G class. By the hybridoma cell lines are produced the anti-annexin-V monoclonal antibodies, with which a diagnostic agent is provided for diagnosis of myocardial infarction and angina pectoris.
    Type: Grant
    Filed: October 22, 1996
    Date of Patent: June 16, 1998
    Assignees: Noboru Kaneko, International Reagents Corporation
    Inventors: Noboru Kaneko, Ryuko Matsuda, Tadahiro Kajita, Yohsuke Ohta
  • Patent number: 5763272
    Abstract: Disclosed are antibodies which specifically bind the amino acid sequence of SEQ ID NO. 1 of collagen I. A hybridoma cell line which produces the antibodies is also disclosed.
    Type: Grant
    Filed: July 9, 1996
    Date of Patent: June 9, 1998
    Assignee: Boehringer Mannheim GmbH
    Inventors: Werner Naser, Brigitte Drager, Ulrich Essig, Christa Hubner-Parajsz, Erasmus Huber
  • Patent number: 5763274
    Abstract: An antibody against peanut agglutinin-(PNA)-binding glycoprotein on the surface of cells is named 103B2 and registered at the German Collection of Microorganisms and Cell Cultures GmbH, DSMZ, under the Budapest Treaty.
    Type: Grant
    Filed: August 16, 1996
    Date of Patent: June 9, 1998
    Assignee: Eberhard-Karls-Universitat Tubingen
    Inventors: Hans-Jorg Buhring, Andrew Zannettino, Paul J. Simmons
  • Patent number: 5747037
    Abstract: Antibodies that bind a protein gp39 (also referred to as CD40 ligand) are disclosed. Preferably, the antibodies are monoclonal antibodies of an IgG1 isotype and bind human gp39. In a preferred embodiment, an antibody of the invention binds an epitope recognized by a monoclonal antibody 24-31, produced by a hybridoma 24-31 (ATTC Accession No. HB11712) or binds an epitope recognized by a monoclonal antibody 89-76, produced by a hybridoma 89-76 (ATCC Accession No.HB11713). Pharmaceutical compositions comprising the antibodies of the invention are also disclosed. The antibodies of the invention are useful for inhibiting B cell proliferation and differentiation, T cell responses and for inducing T cell tolerance. Nucleic acid molecules encoding anti-gp39 antibodies, or portions thereof, as well as expression vectors and host cells incorporating said nucleic acid molecules, are also encompassed by the invention.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 5, 1998
    Assignees: Bristol-Myers Squibb Company, Trustees of Dartmouth College
    Inventors: Randolph J. Noelle, Teresa M. Foy, Alejandro Aruffo, Jeffrey A. Ledbetter
  • Patent number: 5744356
    Abstract: A unique monoclonal antibody is provided for determining the functional status of human estrogen receptor protein. The monoclonal antibody will specifically bind and react with an epitope present within the transactivation function, A/B domain of the human estrogen receptor protein. The functional status of the A/B domain is determined by identifying and discriminating among the 8S, 4S, 5S isoforms of the A/B region as these exist in the human estrogen receptor protein.
    Type: Grant
    Filed: July 31, 1995
    Date of Patent: April 28, 1998
    Assignee: Trustees of Boston University
    Inventor: Abdulmaged M. Traish
  • Patent number: 5730979
    Abstract: The present invention relates to a LO-CD2a antibody and methods of using such antibodies or molecules that bind to the same epitope (or a portion thereof) to prevent and inhibit an immune response in human patients, preferably, where the immune response is mediated by the activation and proliferation of T cells or natural killer cells. The administration of an effective amount of the LO-CD2a antibody to a human patient will prevent or inhibit graft rejection, graft versus host disease or autoimmune disease.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: March 24, 1998
    Assignee: Universite Catholique deLouvain
    Inventors: Herve Bazin, Dominuque Latinne
  • Patent number: 5719268
    Abstract: Methods and compositions are provided for the modulation of monocyte binding to endothelial cells, particularly during inflammatory episodes. Compositions are provided which bind to one or both of the monocyte surface membrane protein or the endothelial surface membrane protein which are complementary or result in the adhesion of the monocyte to the endothelial cell. The subject compositions can be used in diagnosis or therapy.
    Type: Grant
    Filed: November 14, 1994
    Date of Patent: February 17, 1998
    Assignee: The Board of Trustees of the Leland Junior Stanford University
    Inventors: Leslie M. McEvoy, Eugene C. Butcher
  • Patent number: 5688657
    Abstract: Monoclonal antibodies, in particular 33.28 and 31.1, and chimeric antibodies, in particular mouse/human chimeric Chi #1 specific for glycoprotein antigens of colon carcinoma-associated antigens which are immunogenic in humans, are disclosed. Such antibodies, and fragments and derivatives thereof, are useful in immunodiagnosis and immunotherapy of human colon, breast, and ovarian cancer, and for purification of antigens which can serve as immunotherapeutic agents. Methods of detecting the colon carcinoma-associated antigen in a sample, and methods for treating subjects having colon, breast, and ovarian carcinomas are disclosed.
    Type: Grant
    Filed: September 12, 1994
    Date of Patent: November 18, 1997
    Assignee: International Bio-Immune Systems, Inc.
    Inventors: Kwong Y. Tsang, Myron Arlen
  • Patent number: 5679583
    Abstract: It is possible with the aid of a monoclonal antibody which is specifically directed against an epitope of amino-terminal procollagen peptide (type III) which is not present on the fragment Col 1, and of a second monoclonal or polyclonal antibody against an epitope of amino-terminal procollagen peptide (type III), to determine said peptide with great accuracy. It is also, possible, with the aid of a monoclonal antibody which is specifically directed against an epitope of amino-terminal procollagen peptide (type III) which is not present in Col 1, to determine with great accuracy said procollagen peptide in body fluids.
    Type: Grant
    Filed: April 5, 1995
    Date of Patent: October 21, 1997
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Dietrich Brocks, Jurgen Punter, Helmut Strecker, deceased, Rupert Timpl, Volkmar Gunzler-Pukall, Henning Hachmann
  • Patent number: 5677181
    Abstract: Antibodies, including monoclonal antibodies, specific for proliferating/angiogenic human endothelial cells such as human umbilical vein endothelial cells and human umbilical artery endothelial cells, and conjugates of these antibodies with a toxin material or label, are useful for inhibition of angiogenesis or for treatment of angiogenesis-dependent disease.
    Type: Grant
    Filed: July 3, 1995
    Date of Patent: October 14, 1997
    Assignee: The Australian National University
    Inventor: Christopher Richard Parish
  • Patent number: 5665595
    Abstract: The present invention provides a composition and method of protecting plants otherwise susceptible to infestation by insects of the orders Lepidoptera and Coleoptera.
    Type: Grant
    Filed: March 18, 1994
    Date of Patent: September 9, 1997
    Assignee: DowElanco
    Inventors: James K. Petell, Kathi J. Halvin
  • Patent number: 5665357
    Abstract: Antibodies which recognize a tumor related antigen designated CA55.1 such as hybridoma 55.1 deposited as ECACC deposit no. 93081901 in which the complementarity determining regions have the following sequences:a) heavy chainCDR1 G Y W I H (SEQ ID NO: 27)CDR2 E V N P S T G R S D Y N E K F K N (SEQ ID NO: 28)CDR3 E R A Y G Y D D A M D Y (SEQ ID NO: 29)b) light chainCDR1 K S S Q S L L N S R T R K N Y L A (SEQ ID NO: 30)CDR2 W A S T R T S (SEQ ID NO: 31)CDR3 K Q S Y T L R T (SEQ ID NO: 32)or a conservative analogue thereof. The peptide ACEHRGSGWC (SEQ ID NO: 26), as displayed on the surface of bacteriophage NCIMB No. 40638, is a mimic of the tumor related antigen CA55.1.
    Type: Grant
    Filed: December 2, 1994
    Date of Patent: September 9, 1997
    Assignee: Zeneca Limited
    Inventors: Michael Samuel Rose, Christopher Boot, Clive Graham Copley, Douglas Stephen Paterson, Susan Margaret Hall, Andrew Firman Wright, David Charles Blakey
  • Patent number: 5663303
    Abstract: The present invention discloses methods for preparing antibodies which bind to specific isoforms of the human retinoic acid receptor-.gamma. (RAR-.gamma.). In addition, several monoclonal antibodies are described which bind to human RAR-.gamma., but not to mouse or which bind to RAR-.gamma.1, but not to RAR-.gamma.2. Methods and kits are described which allow one to detect the isotype of RAR-.gamma. which is expressed in a test sample. Such methods are useful in determining the tissue specific pattern of expression of various RAR-.gamma. isoforms.
    Type: Grant
    Filed: November 4, 1991
    Date of Patent: September 2, 1997
    Assignees: Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique, Universite Louis Pasteur, Strasbourg I, E.R. Squibb & Sons, Inc.
    Inventors: Cecille Rochette-Egly, Yves Lutz, Michael Saunders, Isabelle Scheuer, Marie-Pierre Gaub, Pierre Chambon
  • Patent number: 5660994
    Abstract: The invention relates to the identification of insoluble cytoskeletal proteins, or fragments thereof, which are characteristic of the origin of the tissue. The invention relates as well to the method for detecting such proteins by breaking down and solubilizing the protein for immunological detection and quantitation. The method allows detection of tissue lesions or other pathological foci and metastases.
    Type: Grant
    Filed: March 1, 1995
    Date of Patent: August 26, 1997
    Assignee: Progen Biotechnik GmbH
    Inventors: Gerda Bruder-Heid, Werner Wilhelm Franke
  • Patent number: 5658743
    Abstract: The invention relates to a new antigen termed BLA-36 specifically expressed on the surface of Hodgkin's cells, Reed-Sternberg cells and B lymphocytes, and to a new monoclonal antibody (anti-BLA-36) specific thereto. The antigen is characterized by the following properties:a molecular weight of about 36,000 D;the presence of an epitope recognized by antibody to said protein;specific expression by Hodgkin's cells and Reed-Sternberg cells in all subsets of Hodgkin's disease, and by activated and early proliferating B cells;no expression by T cells;capability of reacting with its antibody in both frozen and fixed/paraffin embedded tissues;a function associated with the growth of cells capable to express said antigen protein.
    Type: Grant
    Filed: April 18, 1994
    Date of Patent: August 19, 1997
    Assignee: University of Southern California
    Inventors: Ashraf Imam, Clive R. Taylor
  • Patent number: 5652110
    Abstract: The invention relates to monoclonal antibodies to the .alpha.v.beta.3 integrin receptor known to be expressed in large amounts on the surface of osteoclasts and accordingly, associated with bone resorption. The disclosed monoclonal antibodies are believed to recognize unique epitopes on .alpha.v.beta.3 and are useful in the treatment of conditions associated with excessive bone resorption and/or in the inhibition of tumor cell growth.
    Type: Grant
    Filed: May 2, 1995
    Date of Patent: July 29, 1997
    Assignee: Genentech, Inc.
    Inventors: Kyung Jin Kim, Michael A. Horton, Sarah C. Bodary, Anan Chuntharapai
  • Patent number: 5652109
    Abstract: The invention relates to monoclonal antibodies to the .alpha.v.beta.3 integrin receptor known to be expressed in large amounts on the surface of osteoclasts and accordingly, associated with bone resorption. The disclosed monoclonal antibodies are believed to recognize unique epitopes on .alpha.v.beta.3 and are useful in the treatment of conditions associated with excessive bone resorption and/or in the inhibition of tumor cell growth.
    Type: Grant
    Filed: May 2, 1995
    Date of Patent: July 29, 1997
    Assignee: Genentech, Inc.
    Inventors: Kyung Jin Kim, Michael A. Horton, Sarah C. Bodary, Anan Chuntharapai
  • Patent number: 5645997
    Abstract: The present invention relates to the diagnosis of multiple sclerosis. More specifically, this invention relates to an assay for detecting antigen(s) associated with multiple sclerosis. The present invention also relates to the generation of hybridomas which produce monoclonal antibodies which are specific for the multiple sclerosis-associated antigens. The present invention's use is in diagnosing multiple sclerosis and in routine follow-up monitoring of multiple sclerosis patients as to disease progression or response to therapy.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 8, 1997
    Assignees: Molecular Rx, Inc., Cell Med, Inc.
    Inventors: Ellis L. Kline, Daniel H. Zimmerman
  • Patent number: 5643736
    Abstract: Monoclonal antibodies specific for normal human osteogenic cell subsets and the monoclonal hybridoma cell lines that synthesize and secrete these monospecific antibodies, as well as the uses of the monoclonal antibodies for diagnostic and/or therapeutic purposes.
    Type: Grant
    Filed: February 6, 1995
    Date of Patent: July 1, 1997
    Assignees: Osiris Therapeutics, Inc., Case Western Reserve University
    Inventors: Scott P. Bruder, Arnold I. Caplan, Stephen E. Haynesworth
  • Patent number: 5639656
    Abstract: The invention provides compositions and methods for use in detecting benign prostate hyperplasia (BPH) and for differentiating BPH from normal prostate tissues and prostate cancer. Disclosed are monoclonal antibodies (MAbs) directed against a highly restricted biological marker of BPH, hybridoma cells secreting such MAbs and various methods for making and using BPH-specific antigens and antibodies, including methods and kits for the detection of BPH antigens and the diagnosis and therapy of BPH.
    Type: Grant
    Filed: March 31, 1994
    Date of Patent: June 17, 1997
    Assignee: Medical College of Hampton Road
    Inventor: George L. Wright, Jr.
  • Patent number: 5635389
    Abstract: Antibodies, both polyclonal and monoclonal, recognize and bind human villin. Hybridomas, producing monoclonal antibodies which bind human villin, are also provided.
    Type: Grant
    Filed: April 13, 1995
    Date of Patent: June 3, 1997
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medical
    Inventors: Daniel Louvard, Brigitte Dudouet, Sylvie Robine, Monique Arpin, Eric Pringault, Alphonse Garcia
  • Patent number: 5627073
    Abstract: Isolated CHF (also referred to cardiac hypertrophy factor or cardiotrophin-1), isolated DNA encoding CHF, hybridomas and cell lines producing antibodies to CHF, and recombinant or synthetic methods of preparing CHF are disclosed. These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: May 6, 1997
    Assignees: Genentech, Inc., The Regents of the University of California
    Inventors: Joffre Baker, Kenneth Chien, Kathleen King, Diane Pennica, William Wood
  • Patent number: 5620889
    Abstract: The present invention provides a panel of monoclonal antibodies and binding proteins which specifically bind to human Fas antigen. Some of the antibodies and binding proteins are capable of stimulating T cell proliferation, inhibiting binding of anti-Fas CH-11 monoclonal antibody to cells expressing Fas antigen, blocking anti-Fas CH-11 monoclonal antibody-mediated lysis of cells, and blocking Fas ligand-mediated lysis of cells. The invention also provides for therapeutic compositions comprising the monoclonal antibodies.
    Type: Grant
    Filed: October 13, 1994
    Date of Patent: April 15, 1997
    Assignee: Immunex Corporation
    Inventors: David H. Lynch, Mark R. Alderson
  • Patent number: 5616492
    Abstract: Monoclonal antibodies and a method capable of detecting BBI metabolites in a sample of body fluid or tissue are provided.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: April 1, 1997
    Assignees: Trustees of the University of Pennsylvania, University of Rochester
    Inventors: Ann R. Kennedy, Cameron J. Koch, Edith M. Lord, Xingsheng Wan
  • Patent number: 5610058
    Abstract: A monoclonal antibody specific for a unique subset of extra-villous trophoblast in human placental tissue, the cell line that produces it, and the isolated antigen to which it is directed.
    Type: Grant
    Filed: February 23, 1995
    Date of Patent: March 11, 1997
    Assignee: Isis Innovation Limited
    Inventors: Simon C. Shorter, Bernadette L. Ferry, Phyllis M. Starkey, Ian L. Sargent, Christopher W. G. Redman
  • Patent number: 5604126
    Abstract: Hybridoma 4A11 produces a murine IgM monoclonal antibody specifically against endothelial cells in diseased tissues such as rheumatoid and osteoarthritis synovial tissues, and psoriatic skin. The 4A11 antibody has possible clinical utility for detection of human endothelial cells mainly in inflamed and malignant disease states.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: February 18, 1997
    Assignee: Northwestern University
    Inventor: Alisa E. Koch
  • Patent number: 5597725
    Abstract: DNA sequences encoding novel cadherins, desginated cadherins-4 through -12, are disclosed along with methods and materials for the recombinant production of the same. Antibody substances specific for the novel cadherins and cadherin peptides are disclosed as useful for modulating the natural binding and/or regulatory activities of the cadherins.
    Type: Grant
    Filed: January 26, 1994
    Date of Patent: January 28, 1997
    Assignee: Doheny Eye Institute
    Inventor: Shintaro Suzuki
  • Patent number: 5597726
    Abstract: The present invention relates to a naturally occurring, minimally modified LDL antigen which is present in human atherosclerotic lesions as well as in the serum of a high percentage of patients with coronary artery disease. The invention also comprises antibodies reactive with the antigen, hybridoma cell lines that produce the antibodies of the invention, and methods for using the antibodies in the diagnosis and treatment of atherosclerotic disease.
    Type: Grant
    Filed: March 30, 1995
    Date of Patent: January 28, 1997
    Assignee: Eli Lilly and Company
    Inventors: Thomas F. Bumol, Leslie M. McEvoy